As with most corporate chiefs, Biocon's normally would be pleased with India's proposal to lower the nation's corporate tax rate to 25% from 30%. But, if it means eliminating tax exemptions for investments in research and development, Biocon is opposed.
China's Kelun Pharmaceutical has just opened a $50 million production plant in Almaty (formerly Alma-Ata), just across the border in Kazakhstan. Kelun Kazpharm executives told China's state-run Xinhua news agency the plant is responsible for 70% of the Kazakhstan market for intravenous medicines.
China-focused CRO BioDuro has merged with manufacturing company Formex in the U.S. as part of an apparent reorganization under owner Bridgewest Group with all three companies located in San Diego.
A U.S. court has barred Dr Reddy's Laboratories from selling its generic of AstraZeneca's heartburn drug Nexium after AstraZeneca objected to the Indian drugmaker's use of the color purple for the pills, according to reports.
Dr Reddy's Laboratories has again come under the spotlight of the U.S. Food and Drug Administration which has ordered a third-party audit covering the entire manufacturing network of the company, according to a report by Livemint.
Mumbai-based Sun Pharmaceutical Industries saw net profit slump nearly a third in its financial second quarter as costs related to its purchase of troubled Ranbaxy Laboratories continue to hound operations.
In this day of instant gratification, instant feedback via social media and fast food and fast fashion, General Electric wants to add fast prefabricated drug manufacturing plants to the list.
India's Dr Reddy's Laboratories is looking to increase sales of biosimilars in emerging markets and plans to launch products in Russia as well as licensing deals in Southeast Asia, its chief operating officer told an earnings call, according to a Reuters report.
Swiss-based Novartis will close a manufacturing plant in India, CEO Joe Jimenez said on the Oct. 27 third quarter earnings call, noting that the company has moved on remediation plans following inspections, but still received a U.S. FDA warning letter.
A manufacturing pact in China's Chongqing will see U.S.-based Athenex build two drug manufacturing plants at Banan that will receive local funding for land and construction, the company formerly known as Kinex said in a press release.